Erweiterte Suche

Vasant Narasimhan ist Chief Executive Officer der Novartis AG und Chief Executive Officer der Novartis International AG (eine Tochtergesellschaft der Novartis AG). Er ist ausserdem Mitglied des Verwaltungsrats der Novartis Stiftung und Mitglied des Institute of Medicine, Mitglied der National Academy of Medicine of United States sowie Treasurer & Director bei Pharmaceutical Research & Manufacturers of America. In seiner bisherigen Laufbahn war er Präsident von Novartis Vaccines & Diagnostics, Inc. und Global Head-Development bei Novartis Vaccines & Diagnostics, Inc. sowie Global Head-Development bei Novartis Pharmaceuticals und Global Head-Development bei Sandoz Pharmaceuticals AG. Er erwarb einen Abschluss an der Harvard Medical School, einen Abschluss an der Harvard Kennedy School of Government und einen Bachelor-Abschluss an der University of Chicago.

Narasimhan Mani is currently the Chief Executive Officer at Xiromed LLC since 2019.
Prior to this, he worked as the Director-Global Business Development & Portfolio at Amneal Pharmaceuticals LLC.
He holds an MBA from The Trustees of Columbia University in The City of New York and a doctorate from the University of Georgia.

Sundar Narasimhan is currently the Co-President at Sabre Holdings Corp.
He is also a Senior VP-Product labs & Product Strategy at Sabre Corp.
Previously, he worked as a Product Manager at ITA Software, Inc. from 2011 to 2012.
He also served as the Chief Scientist at Ascent Technology Ltd.
Dr. Narasimhan holds graduate and doctorate degrees from the Massachusetts Institute of Technology, as well as an undergraduate degree from the Indian Institute of Technology Madras.

Narasimhan Raghunathan worked as a Secretary, Compliance Officer & DGM-Finance at KSB Ltd.